Top headlines: Questions over Oxford vaccine data, Vedanta under pressure

Modi bats for One Nation One Election, Keki Mistry says NPAs in real estate will inch up , and more top headlines of the day

AstraZenca
BS Web Team New Delhi
2 min read Last Updated : Nov 26 2020 | 6:10 PM IST
Modi bats for One Nation One Election

Prime Minister Narendra Modi on Thursday pitched for 'One Nation, One Election', saying it is the need of India as polls taking place every few months impact development works. Read more...

AstraZeneca faces more vaccine questions

AstraZeneca Plc and the University of Oxford face mounting questions about their Covid-19 vaccine trial results after acknowledging a manufacturing error. While an announcement earlier this week by Astra and Oxford showed their shot was 70 per cent effective on average in a late-stage study, the scant details released by the UK partners have sparked worries, with some expressing doubts about whether US regulators would clear it. Read more...

NPAs in real estate will inch up: Keki Mistry

Keki Mistry, vice chairman and CEO at HDFC, said at a webinar on Thursday that the benign interest rate regime will continue for the next six to 12 months. "Interest rates are at the lowest in the last four decades. Property prices have gone up in the last many years," Mistry said at a webinar organised by Naredco and APREA today. Read more

Capital account convertibility a process, not an event: RBI governor

Reserve Bank of India (RBI) governor Shaktikanta Das on Thursday said capital account convertibility will be a continued process, rather than an event, even as the country has progressed quite considerably in its quest towards full convertibility and internationalisation of its financial markets. Read more

Vedanta Resources under pressure
 
Vedanta Resources Ltd. has begun sounding out debt holders about the possibility of extending maturities on some of its dollar bonds to reduce refinancing pressures. The mining giant started approaching the investors to discuss possible debt extensions after the company’s failed attempt to delist its India unit, Vedanta Ltd., people familiar with the matter said. Read more..

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusVedanta Resourcestop news of the dayCoronavirus VaccineAstraZeneca

Next Story